Detailed analysis of the “Wounds-Pipeline Review, H2 2016” helps to understand the various types of such products that are currently in use, along with the variants that would gain prominence in the future.
Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Wounds – Pipeline Review, H2 2016, provides an overview of the Wounds (Dermatology) pipeline landscape.
Wound is a breakdown in the protective function of the skin (the loss of continuity of epithelium) with or without loss of underlying connective tissue (i.e. muscle, bone, nerves) following injury to the skin or underlying tissues/ organs caused by surgery, a blow, a cut, chemicals, heat/ cold, friction/ shear force, pressure or as a result of disease, such as leg ulcers or carcinomas. Signs and symptoms include redness or red streaks on the skin surrounding the wound, increased swelling to tenderness at the wound site, pus-like drainage or a foul smell from the wound and body chills or fever.
Key Companies Mentioned:
Aerpio Therapeutics Inc, AlgiPharma AS, AmpliPhi Biosciences Corp, AndroScience Corp, Aridis Pharmaceuticals LLC, Beech Tree Labs Inc, Bio3 Research Srl, Biotec Pharmacon ASA, Blueberry Therapeutics Ltd, Cellphire Inc, CorMedix Inc, Dermala Inc, Destiny Pharma Ltd, Escape Therapeutics Inc, EyeGene Inc, FibroGen Inc, GangaGen Inc, Gene Signal International SA, GlaxoSmithKline Plc, IC-MedTech Inc, Living Cell Technologies Ltd, Madam Therapeutics BV, miRagen Therapeutics Inc, NatureWise Biotech & Medicals Corp, Novan Inc, NuvOx Pharma LLC, Octapharma AG, Omeros Corp, Osiris Therapeutics Inc, Pacific Northwest Biotechnology LLC, Pharmaxis Ltd, ProMetic Life Sciences Inc, RiverTown Therapeutics Inc, RMB-Research GmbH, RXi Pharmaceuticals Corp, Sinclair Pharma Plc, SomaGenics Inc, Stratatech Corp, TGV-Laboratories, Thesan Pharmaceuticals Inc, Topadur Pharma AG, Trophogen Inc, Tumorend LLC, VBS Pharmaceuticals and viDA Therapeutics Inc.
Place a direct purchase order on this report at http://www.orbisresearch.com/contact/purchase/171196 . AND if you have enquire before buying this report visit at http://www.orbisresearch.com/contacts/enquiry-before-buying/171196 .
Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Wounds – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Wounds (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Wounds (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Wounds and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 5, 1, 56, 9 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 13 and 7 molecules, respectively.
Wounds (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Browse the full report @ http://www.orbisresearch.com/reports/index/wounds-pipeline-review-h2-2016 .
List of Tables
Number of Products under Development for Wounds, H2 2016 18
Number of Products under Development for Wounds – Comparative Analysis, H2 2016 19
Number of Products under Development by Companies, H2 2016 20
Number of Products under Development by Companies, H2 2016 (Contd..1) 21
Number of Products under Development by Companies, H2 2016 (Contd..2) 22
Number of Products under Development by Companies, H2 2016 (Contd..3) 23
Number of Products under Investigation by Universities/Institutes, H2 2016 25
Comparative Analysis by Late Stage Development, H2 2016 26
Comparative Analysis by Clinical Stage Development, H2 2016 27
Comparative Analysis by Early Stage Development, H2 2016 28
Comparative Analysis by Unknown Stage Development, H2 2016 29
Products under Development by Companies, H2 2016 30
Products under Development by Companies, H2 2016 (Contd..1) 31
Products under Development by Companies, H2 2016 (Contd..2) 32
Products under Development by Companies, H2 2016 (Contd..3) 33
Products under Development by Companies, H2 2016 (Contd..4) 34
Products under Investigation by Universities/Institutes, H2 2016 35
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 36
Wounds – Pipeline by Aerpio Therapeutics Inc, H2 2016 37
Wounds – Pipeline by AlgiPharma AS, H2 2016 38
Wounds – Pipeline by AmpliPhi Biosciences Corp, H2 2016 39
Wounds – Pipeline by AndroScience Corp, H2 2016 40
Wounds – Pipeline by Aridis Pharmaceuticals LLC, H2 2016 41
Wounds – Pipeline by Beech Tree Labs Inc, H2 2016 42
Wounds – Pipeline by Bio3 Research Srl, H2 2016 43
Wounds – Pipeline by Biotec Pharmacon ASA, H2 2016 44
Wounds – Pipeline by Blueberry Therapeutics Ltd, H2 2016 45
Wounds – Pipeline by Cellphire Inc, H2 2016 46
Wounds – Pipeline by CorMedix Inc, H2 2016 47
Wounds – Pipeline by Dermala Inc, H2 2016 48
Wounds – Pipeline by Destiny Pharma Ltd, H2 2016 49
Wounds – Pipeline by Escape Therapeutics Inc, H2 2016 50
Wounds – Pipeline by EyeGene Inc, H2 2016 51
Wounds – Pipeline by FibroGen Inc, H2 2016 52
Wounds – Pipeline by GangaGen Inc, H2 2016 53
Wounds – Pipeline by Gene Signal International SA, H2 2016 54
Wounds – Pipeline by GlaxoSmithKline Plc, H2 2016 55
Wounds – Pipeline by IC-MedTech Inc, H2 2016 56
Wounds – Pipeline by Living Cell Technologies Ltd, H2 2016 57
Wounds – Pipeline by Madam Therapeutics BV, H2 2016 58… Continued
Request a sample for this report @ http://www.orbisresearch.com/contacts/request-sample/171196 .
– The pipeline guide provides a snapshot of the global therapeutic landscape of Wounds (Dermatology).
– The pipeline guide reviews pipeline therapeutics for Wounds (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Wounds (Dermatology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Wounds (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Wounds (Dermatology)
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Wounds (Dermatology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Wounds (Dermatology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customised reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialisation. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +912064101019
Email ID: email@example.com
Follow Us on Linkedin: https://www.linkedin.com/company/orbis-research